SYO 2248
Alternative Names: SYO-2248Latest Information Update: 07 Feb 2025
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 26 Dec 2024 Preclinical trials in Breast cancer in South Korea (PO) prior to December 2024 (Samyang Biopharmaceuticals Corporation pipeline, December 2024)